This is what arrives.
One real molecule, unedited, exactly as the platform produced it — the structure, the two steps that build it, what it is likely to do in the body, and a plain account of what it is not.
Its original run published 1.00, normalised to its own batch. For two months we showed a ceiling of 0.54 or below instead, because nothing in the system could score one molecule on its own. That is now built, and the number is 0.35 — a measured value, every term of it reproducible. The bound we published was true, and it sat 55% above the answer.
Three figures moved and all three moved down. Pharmacophore fit was 0.98 on an axis we have since corrected; on the fixed axis it is 0.27. Selectivity was 6.7× and is 4.84×. Synthetic accessibility reads 0.79 rather than 0.74 because the score uses a blend of the SA heuristic and a retrosynthetic score, and only the first half was ever shown. Structure, route and ADMET are unaffected by any of it.
Two things we had not said. This molecule fires three structural alerts — it carries an alpha-keto-amide, which is reactive — and the 15% penalty for them is already inside the 0.35. And it is scored whole-body: asked for a brain-penetrant candidate it is rejected, because its predicted blood-brain-barrier permeability falls below the floor we require for a CNS target. This dossier stands as a worked example of the output and of the route. It is not a recommendation to make this compound.
A nutrient-sensing / autophagy senomorphic.
The aging-signature readout.
A mechanistic structural prior, disclosed, not a lifespan claim (see the methods note). It tells you where the candidate is predicted to move the aging signature.
Relative, within this candidate -- not a claim that any tissue gets younger. The thymus row is greyed because its clock is built from the immune clock by hand and contains no thymus measurement; it is shown rather than hidden so the ranking is not quietly reordered to flatter us, but it is not evidence.
A two-step route, because it was built from reactions, not guessed.
Each atom is traced to its origin synthon, so the route is true attribution from the recipe, not post-hoc explanation. Building blocks here are drawn from the design library; for a live program we map candidates to catalogue building blocks carrying supplier part numbers before hand-off. A catalogue match is not a stock check — we hold no supplier account, so we cannot confirm anything is available to order.
- Novel chemotype: similarity to known geroprotectors is low (≈0.15), a freedom-to-operate signal, not a red flag, but it also means there is no close precedent.
- The phenotype and clock-reversal figures are mechanistic priors, disclosed, not validated against lifespan.
- This molecule comes from an earlier run that predates our binding-plausibility and lifespan-prior scoring, so those are not reported here; a re-score would populate them.
- GQ-259 is a computational hypothesis for medicinal chemistry, not an approval-ready compound. It requires synthesis and wet-lab validation.
